Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 3:55 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 1,787 matching trials from the live ClinicalTrials.gov search.
Conditions
Solid Tumor
Interventions
Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
16
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Conditions
Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Mixed Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIC Uterine Corpus Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer
Interventions
Cisplatin, Doxorubicin Hydrochloride, Filgrastim, Paclitaxel, Pegfilgrastim
Drug · Biological
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
9
States / cities
Hartford, Connecticut • New Britain, Connecticut • Chicago, Illinois + 6 more
Conditions
Squamous Cell Carcinoma, Carcinoma of Head and/or Neck
Interventions
Taxotere, Cisplatin, 5-Fluorouracil, Leucovorin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions
Cisplatin, Laboratory Biomarker Analysis, Paclitaxel, Veliparib
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
25
States / cities
Los Angeles, California • Augusta, Georgia • Chicago, Illinois + 18 more
Conditions
Head and Neck Cancer
Interventions
CUDC-101, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Stanford, California • Aurora, Colorado • Shreveport, Louisiana + 4 more
Conditions
Lymphoma, B-Cell
Interventions
CC-220, Polatuzumab vedotin, Rituximab, Tafasitamab, Gemcitabine, Cisplatin, Dexamethasone, Bendamustine, Lenalidomide
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Sioux Falls, South Dakota
Conditions
Cervical Cancer
Interventions
Pembrolizumab, Paclitaxel, Cisplatin, Carboplatin, Bevacizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Miami, Florida
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
34
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more
Conditions
Epithelial Ovarian Cancer, Primary Peritoneal Cancer
Interventions
Topotecan, Cisplatin, Paclitaxel
Drug
Lead sponsor
John P. Fruehauf
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Orange, California
Conditions
Peritoneal Neoplasms, Stomach Neoplasms
Interventions
CHPP with cisplatin
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-Small Cell Lung Cancer
Interventions
Livmoniplimab, Budigalimab, Pembrolizumab, Pemetrexed, Cisplatin, Carboplatin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
19
States / cities
La Jolla, California • Pembroke Pines, Florida • Winter Haven, Florida + 16 more
Conditions
Extensive-Stage Small Cell Lung Cancer
Interventions
sunitinib
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Conditions
Triple Negative Breast Cancer
Interventions
Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT
Drug · Biological · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
El Segundo, California
Conditions
Lymphoma
Interventions
rituximab, cisplatin, cytarabine, dexamethasone, sargramostim
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
20
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 17 more
Conditions
Diseases of Oesophagus Stomach and Duodenum
Interventions
Dexamethasone, Diphenhydramine, Famotidine, Mitomycin C, Cisplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma
Interventions
Durvalumab, Tremelimumab, Cisplatin (dose level 4), Cisplatin (dose level 3), Carboplatin (dose level 1), Carboplatin (dose level 2), Etoposide (dose level 1), Etoposide (dose level 2), Paclitaxel, Pemetrexed, External beam radiation (dose level 1), External beam radiation (dose level 2), External beam radiation (hyperfractionated), Cisplatin (dose level 1), Cisplatin (dose level 2), External beam radiation (standard)
Drug · Radiation
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 110 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
3
States / cities
Tucson, Arizona • Aurora, Colorado • Houston, Texas
Conditions
Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Onalespib, Pharmacological Study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Neoplasms, Head and Neck
Interventions
Lapatinib, Chemoradiation, Placebo
Drug · Radiation · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 70 Years
Enrollment
688 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
5
States / cities
Springfield, Illinois • St Louis, Missouri • New York, New York + 2 more
Conditions
Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Stage III Extrahepatic Bile Duct Cancer, Stage III Intrahepatic Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IVA Extrahepatic Bile Duct Cancer, Stage IVA Hilar Cholangiocarcinoma, Stage IVA Intrahepatic Cholangiocarcinoma, Stage IVB Extrahepatic Bile Duct Cancer, Stage IVB Hilar Cholangiocarcinoma, Stage IVB Intrahepatic Cholangiocarcinoma, Unresectable Extrahepatic Bile Duct Carcinoma
Interventions
Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study, Ricolinostat
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
cisplatin, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Conditions
Non-small Cell Lung Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Conditions
ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma
Interventions
Cisplatin, Etoposide, Mitotane, Quality-of-Life Assessment
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Ann Arbor, Michigan • St Louis, Missouri • Houston, Texas